Research map: SARS-CoV-2 resistance pathways to EDP-235

Back to the article

Papers in this map

  1. UCSF ChimeraX : Tools for structure building and analysis · Elaine C. Meng · 2023 · 4770 citations · Cited by this paper
  2. Envelope protein residue E152 confers enhanced GAS6-dependent cell entry to the African Zika virus strain MR766 · 2026 · Related
  3. GISAID: Global initiative on sharing all influenza data – from vision to reality · Yuelong Shu · 2017 · 3604 citations · Cited by this paper
  4. Recombinant polyclonal antibody GIGA-2339 potently and pan-genotypically neutralizes hepatitis B virus · 2026 · Related
  5. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 · Jennifer Hammond · 2022 · 2231 citations · Cited by this paper
  6. Fluorescence polarization–based high-throughput screening identifies SAM-competitive inhibitors of monkeypox virus N7-methyltransferase · 2026 · Related
  7. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19 · Dafydd R. Owen · 2021 · 1996 citations · Cited by this paper
  8. Human monoclonal antibodies from donors vaccinated with recombinant vaccinia vaccine targeting A35 and B6 effectively inhibit orthopoxvirus spread and infection · 2026 · Related
  9. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets · Andreas Wilm · 2012 · 1572 citations · Cited by this paper
  10. Nanoparticles in viral pneumonia: diagnosis, therapy, and prevention · 2026 · Related
  11. Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States · Jennifer L. Harcourt · 2020 · 632 citations · Cited by this paper
  12. A subset of histamine H4 receptor antagonists prevents B lymphocyte proliferation induced by BCR/TLR9 engagement or EBV infection · 2026 · Related
  13. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19 · Yuto Unoh · 2022 · 614 citations · Cited by this paper
  14. A stapled viral peptide blocks HSV-2 from infecting human cervical cells · 2026 · Related
  15. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir · Sho Iketani · 2022 · 500 citations · Cited by this paper
  16. Human cytomegalovirus terminase inhibitors letermovir, tomeglovir, and the halogenated benzimidazoles modify DNA cleavage/packaging to generate a super-genomic DNA species by cleavage site skipping · 2026 · Related
  17. Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations · Karthik Gangavarapu · 2023 · 389 citations · Cited by this paper
  18. Analysis of ibuzatrelvir's activity against SARS-CoV-2 circulating variants and in vitro resistance mutations · 2026 · Related
  19. Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding · Nikki E. Freed · 2020 · 299 citations · Cited by this paper
  20. Why is the Omicron main protease of SARS-CoV-2 less stable than its wild-type counterpart? A crystallographic, biophysical, and theoretical study. · 2025 · Related
  21. A set of monomeric near-infrared fluorescent proteins for multicolor imaging across scales · Mikhail E. Matlashov · 2020 · 235 citations · Cited by this paper
  22. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system · Yuyong Zhou · 2022 · 230 citations · Cited by this paper
  23. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir · Yinkai Duan · 2023 · 191 citations · Cited by this paper
  24. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors · Seyed Arad Moghadasi · 2023 · 185 citations · Cited by this paper
  25. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir · Dirk Jochmans · 2023 · 179 citations · Cited by this paper
  26. The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition · Michael Dominic Sacco · 2022 · 155 citations · Cited by this paper
  27. Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19 · Jennifer Hammond · 2024 · 145 citations · Cited by this paper
  28. Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19 · Hiroshi Yotsuyanagi · 2024 · 122 citations · Cited by this paper
  29. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir · Xiangrui Jiang · 2023 · 117 citations · Cited by this paper
  30. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL pro Reporter Assay · Heather M. Froggatt · 2020 · 116 citations · Cited by this paper
  31. Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19 · Bin Cao · 2024 · 114 citations · Cited by this paper
  32. Designing a Green Fluorogenic Protease Reporter by Flipping a Beta Strand of GFP for Imaging Apoptosis in Animals · Qiang Zhang · 2019 · 105 citations · Cited by this paper
  33. Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir · Zilei Xia · 2021 · 104 citations · Cited by this paper
  34. Nirmatrelvir Resistance—de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure—a Case Report · Neta S. Zuckerman · 2023 · 104 citations · Cited by this paper
  35. Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19 · Hengrui Liu · 2022 · 99 citations · Cited by this paper
  36. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir · Maki Kiso · 2023 · 86 citations · Cited by this paper
  37. Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2 · Yosuke Hirotsu · 2023 · 80 citations · Cited by this paper
  38. Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir · Xiaoxin Chen · 2024 · 76 citations · Cited by this paper
  39. Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites · Sho Iketani · 2022 · 66 citations · Cited by this paper

Source: OpenAlex (CC0)